In this study, based on a cancer-immune cycle weighted gene co-expression network analysis and in vivo/in vitro experiments, we found that recombination signal binding protein for immunoglobulin kappa J region (RBPJ, an inhibitory transcription factor of Notch pathway5) could be used as a biomarker to evaluate “the killing of CD8+ T cells targeting tumor cells” and “the biological function of HCC cells”. The gene discussed is CD8A; the disease is neoplasm.